Key Decisions in HIV Care: Data on Long-Acting Injectable PrEP

In this episode, Jason Schafer, PharmD, MPH, explores the data for long-acting injectable pre-exposure prophylaxis (PrEP).

Listen as he gives his perspectives on the:

• PrEP pipeline and the importance of having options for patients with differing preferences
• FDA approval of long-acting cabotegravir for PrEP
• HPTN 083 and 084 studies of long-acting cabotegravir for PrEP compared with oral emtricitabine/tenofovir disoproxil fumarate
• Safety data on long-acting cabotegravir for PrEP
• CDC recommendations on the management of injection-site reactions with cabotegravir for PrEP

Presenter:
Jason Schafer, PharmD, MPH
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania 

Follow along with the slides at:
https://bit.ly/3tbvEPK

See the entire program at: 
https://bit.ly/3q2DlGd